Literature DB >> 12586776

Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.

Sophie F Doisneau-Sixou1, Philippe Cestac, Sarah Chouini, Jason S Carroll, Andrew D Hamilton, Said M Sebti, Marc Poirot, Patrick Balaguer, Jean-Charles Faye, Robert L Sutherland, Gilles Favre.   

Abstract

Activation of estrogen receptors (ERs) by estrogens triggers both ER nuclear transcriptional activity and Src/Ras/Erks pathway-dependent mitogenic activity. The present study implicates prenylated proteins in both estrogenic actions. The farnesyltransferase and geranylgeranyltransferase I inhibitors (FTI-277 and GGTI-298, respectively) antagonize estradiol-stimulated cell cycle progression, progesterone receptor, cyclin D1, and c-Myc expression. In contrast, the inhibitors markedly stimulate transcription from two genes containing estrogen response elements, both in the absence and presence of estradiol. The pure antiestrogen ICI 182,780 inhibits by more than 85% these effects on transcription. We demonstrate that both FTI-277 and GGTI-298 increase the association of steroid receptor coactivator-1 with ER alpha and FTI-277 decreases the association of ER alpha with the histone deacetylase 1, a known transcriptional repressor. In addition, FTI-277 has no marked effect on the association of the two corepressors, nuclear receptor corepressor and silencing mediator of retinoid and thyroid receptor with ER alpha, whereas GGTI-298, similar to tamoxifen, clearly increased these associations. Together, these results demonstrate that prenylated proteins play a role in estradiol stimulation of proliferation and progesterone receptor expression. However, they antagonize the ability of ER alpha to stimulate estrogen response element-dependent transcriptional activity, acting presumably through coregulator complex formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586776     DOI: 10.1210/en.2002-220726

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

Authors:  Florence Dalenc; Claire Giamarchi; Mélissa Petit; Marc Poirot; Gilles Favre; Jean-Charles Faye
Journal:  Breast Cancer Res       Date:  2005-11-21       Impact factor: 6.466

2.  Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

Authors:  Fabrice Journe; Carole Chaboteaux; Nicolas Magne; Hugues Duvillier; Guy Laurent; Jean-Jacques Body
Journal:  Breast Cancer Res       Date:  2005-12-12       Impact factor: 6.466

3.  Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.

Authors:  Philippe Cestac; Guillaume Sarrabayrouse; Claire Médale-Giamarchi; Philippe Rochaix; Patrick Balaguer; Gilles Favre; Jean-Charles Faye; Sophie Doisneau-Sixou
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

Review 4.  The role of Src kinase in macrophage-mediated inflammatory responses.

Authors:  Se Eun Byeon; Young-Su Yi; Jueun Oh; Byong Chul Yoo; Sungyoul Hong; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2012-11-11       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.